Sequana Medical 2022 Investor Presentation - Fluid Overload Treatment

Sequana Medical presents its innovative solutions for treating drug-resistant fluid overload in liver disease, heart failure, and cancer patients. The company discusses its flagship alfapump® system, which has regulatory approval in Europe and is undergoing clinical investigation in the United States and Canada via the POSEIDON Study, alongside its DSR® therapy in development.